39th week of 2010 patent applcation highlights part 55 |
Patent application number | Title | Published |
20100247549 | MONOCLONAL ANTIBODIES AGAINST DENGUE AND OTHER VIRUSES WITH DELETION IN FC REGION - The present invention relates to a variant of a parent polypeptide comprising an Fc region, which variant binds an Fc gamma receptor (FcγR) with lower affinity than the parent polypeptide and comprises a deletion of at least one amino acid in about position 100 to about position 150 in the Fc region and related nucleic acids, vectors, host cells and methods of producing the variant and methods for preventing or treating a disorder in a mammal. | 2010-09-30 |
20100247550 | SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS AND USES OF SAID REPLIKIN SCAFFOLDS - The present invention provides a new class of peptides related to rapid replication and high human mortality, and their use in diagnosing, preventing and treating disease including vaccines and therapeutics for emerging viral diseases and methods of identifying the new class of peptides and related structures. | 2010-09-30 |
20100247551 | Use of Lipocalin 2 in the Regulation of Insulin Sensitivity - Methods of identifying compounds that modulate lipocalin 2 activity or expression are described, as are methods of reducing insulin resistance or increasing insulin sensitivity by administering compounds that modulate lipocalin 2 expression. Methods of diagnosing insulin resistance or related conditions, by measuring lipocalin 2 activity, are also described. | 2010-09-30 |
20100247552 | PAK MODULATORS - The present invention provides methods for treating fragile X syndrome and/or other neurodevelopmental disorders by administering p21-activated kinase (PAK) modulators to a patient suffering from, susceptible to, and/or exhibiting one or more symptoms of FXS and/or other neurodevelopmental disorders. The present invention provides PAK modulators and pharmaceutical compositions comprising PAK modulators. The present invention further provides methods for identifying and/or characterizing PAK modulators. | 2010-09-30 |
20100247553 | Goodpasture Antigen Binding Protein - The present invention provides isolated nucleic acid sequences and expression vectors encoding the Goodpasture antigen binding protein (GPBP), substantially purified GPBP, antibodies against GPBP, and methods for detecting GPBP. | 2010-09-30 |
20100247554 | USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS - This disclosure concerns antimicrobial compositions and methods for immunoenhancement, for example methods of increasing production of a type I interferon (IFN) in response to pathogen infection, by administration of a TAM receptor inhibitor. In certain embodiments, the disclosure concerns methods of using a TAM receptor inhibitor to treat a viral or bacterial infection in a subject. | 2010-09-30 |
20100247555 | REVERSIBLY INHIBITED ANTIBODIES FOR IMMUNE CELL STIMULATION - The invention provides methods for stimulating the immune system using antibodies capable of activating immune cells, such as T cells, the antibodies having reversibly inhibited antigen binding sites. Selective activation of the antigen binding sites at a site where an immune response is required (e.g. by irradiation) leads to a corresponding activation of the immune response at that site. Surprisingly good results are achieved even though the antibodies do not possess any targeting moiety which causes them to selectively accumulate at the site where immune cell activation is required. | 2010-09-30 |
20100247556 | METHOD FOR ACTIVATION OF HELPER T CELL AND COMPOSITION FOR USE IN THE METHOD - Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others. | 2010-09-30 |
20100247557 | Immunostimulant Composition Comprising At Least One Toll-Like Receptor 7 Or Toll-Like Receptor 8 Agonist And A Toll-Like Receptor 4 Agonist - The invention relates to an immunostimulant composition comprising at least one Toll-like receptor 7 or Toll-like receptor 8 agonist and a receptor 4 agonist. The inventive composition can also comprise a vaccine antigen. | 2010-09-30 |
20100247558 | PEPTIDES INDUCING A CD4i CONFORMATION IN HIV gp120 WHILE RETAINING VACANT CD4 BINDING SITE - A novel peptides are complexed with HIV-I envelope protein gp120, and causes the protein to assume a CD4i conformation but without occluding the CD4 binding-site of gp120. This peptide-gp120 complex is immunogenic and, upon immunization of subjects, induces broadly-neutralizing antibodies directed to the CD4 binding site of gp120. The peptide preferably consists of a sequence of 8-20 amino acid residues which comprises (a) a core sequence Arg-Xaa | 2010-09-30 |
20100247559 | WEST NILE VIRUS VACCINE, AND METHOD FOR PRODUCTION THEREOF - The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient. | 2010-09-30 |
20100247560 | MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF - Modified polypeptides based on the | 2010-09-30 |
20100247561 | POLYPEPTIDES FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AGAINST STAPHYLOCOCCUS AUREUS - The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1, uses of such polypeptides, and expression systems for producing such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length | 2010-09-30 |
20100247562 | Complexes Derived from Heterohybrid Cells and Uses Thereof - The present invention relates, generally, to pharmaceutical compositions comprising Heat Shock Proteins (HSPs) and HSP complexes recovered from heterohybrid cells that are generated from the fusion of a first type of cell (Type I) with a second type of cell (Type II). In further embodiments, the present invention relates to preparing HSPs and/or HSP complexes recovered from heterohybrid, and to methods to treat and/or prevent diseases, such as cancer and infectious diseases by administering a pharmaceutical composition comprising a HSP and/or HSP complex recovered from heterohybrid cells that are generated from the fusion of a first type of cell (Type I) with a second type of cell (Type II). | 2010-09-30 |
20100247563 | TOPICAL SKIN CARE FORMULATIONS - Disclosed is a topical skin care composition comprising: (a) a combination of the following extracts: | 2010-09-30 |
20100247564 | METHODS AND COMPOSITIONS FOR THE USE OF SARGASSUM FUSIFORME FOR THE INHIBITION OF HIV-1 INFECTION - The methods, kits, articles, and compositions of the invention feature a natural product (e.g., | 2010-09-30 |
20100247565 | Chimeric sindbis-eastern equine encephalitis virus and uses thereof - The present invention discloses a chimeric alphavirus comprising a Sindbis virus cDNA fragment and an Eastern equine encephalitis virus cDNA fragment. The present also discloses the use of this chimeric alphavirus as vaccines and in serological and diagnostic assays. | 2010-09-30 |
20100247566 | CHOLERA VACCINES - The methods and compositions of the present invention are directed to a vaccine against | 2010-09-30 |
20100247567 | COMPOSITION AND METHOD FOR CONTROLLING INTESTINAL PATHOGENIC ORGANISMS - An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of | 2010-09-30 |
20100247568 | NOVEL ADJUVANT - The present invention provides a vaccine adjuvant composition which is used in combination with an allergen vaccine, infection vaccine or tumor vaccine. The present invention specifically provides a vaccine adjuvant composition comprising hemozoin or β-hematin and being used in combination with an allergen vaccine, infection vaccine or tumor vaccine, and a vaccine composition comprising the vaccine adjuvant composition and an allergen vaccine, infection vaccine or tumor vaccine | 2010-09-30 |
20100247569 | Influenza A Virus Vaccines and Inhibitors - The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development. | 2010-09-30 |
20100247570 | High Mannose Glycoprotein Epitopes - Glycoproteins containing high mannose oligosaccharides are obtained and used to generate antibody to the mannose portion of the molecule. Such antibodies can be used in a diagnostic assay. The glycoproteins can be used to generate neutralizing antibody. | 2010-09-30 |
20100247571 | METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS - Immunogenic compositions comprising partially glycosylated viral glycoproteins for use as vaccines against viruses are provided. Vaccines formulated using mono-, di-, or tri-glycosylated viral surface glycoproteins and polypeptides provide potent and broad protection against viruses, even across strains. Pharmaceutical compositions comprising monoglycosylated hemagglutinin polypeptides and vaccines generated therefrom and methods of their use for prophylaxis or treatment of viral infections are disclosed. Methods and compositions are disclosed for influenza virus HA, NA and M2, RSV proteins F, G and SH, Dengue virus glycoproteins M or E, hepatitis C virus glycoprotein E1 or E2 and HIV glycoproteins gp120 and gp41. | 2010-09-30 |
20100247572 | VIRUSES ENCODING MUTANT MEMBRANE PROTEIN - A method to prepare viruses with a mutant membrane protein gene, and viruses obtained by the method, are provided. | 2010-09-30 |
20100247573 | Stabilization of Vaccines by Lyophilization - This invention provides pharmaceutical compositions, such as vaccines, and methods of making and using such compositions. | 2010-09-30 |
20100247574 | CHIMERIC NEWCASTLE DISEASE VIRUS VLPs - The present invention discloses and claims chimeric virus like particles (VLPs) that express and/or contains Newcastle disease matrix protein. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising chimeric VLPs of the inventions. The invention also includes methods of making and administrating chimeric VLPs to vertebrates, including methods of inducing immunity to infections. | 2010-09-30 |
20100247575 | AGENTS FOR PROMOTING IGA PRODUCTION - The present invention provides | 2010-09-30 |
20100247576 | NUCLEOTIDE AND AMINO ACID SEQUENCES ENCODING AN EXPORTED PROTEIN 1 DERIVED FROM PLASMODIUM VIVAX AND USES THEREOF - The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of | 2010-09-30 |
20100247577 | TR1 CELLS, MESENCHYMAL STEM CELLS AND USES THEREOF - The present invention relates to compositions comprising Tr1 cells and mesenchymal stem cells and methods for treating an autoimmune disease, an allergic disease or an inflammatory disease. | 2010-09-30 |
20100247578 | CARRIER SYSTEM FOR BIOLOGICAL AGENTS CONTAINING ORGANOSILICON COMPOUNDS AND USES THEREOF - The invention relates to a novel organosilicon carrier system for biological agents that is produced via a simple, stable and reproducible preparation process that is capable of maintaining tertiary protein structure and biological activity of the proteins and/or other biological agents in the mixture, whereby the carrier system is obtainable by mixing one or more organosilicon compounds, selected from the group comprising organosilicon, sugar organosilicon, amino sugar organosilicon compounds, their derivatives, salts and/or the vesicles formed from them, with one or more biological agents, selected from the group comprising antigens, preantigens, antigen conjugates, antibodies, pre-antibodies, antibody conjugates, allergens, allergen extracts, nucleic acids, plasmids, proteins, peptides, pharmaceutical agents, immunologically active substances and/or cosmetics, in solution at a pH value between 7 and 8, preferably 7.4, followed by homogenisation or sonication of the mixture, followed by sterile filtration of the mixture, followed by lyophilisation. | 2010-09-30 |
20100247579 | THERAPEUTIC AGENT FOR CANCER - The present invention relates to a method for treatment of cancer, which comprises the following steps (A) and (B): (A) applying a treatment which induces the reduction in lymphocytes to a patient; and (B), subsequent to step (A), administering lymphocytes to the patient promptly. The present invention also relates to a cancer therapeutic agent and a cancer treatment kit for use in the method. When the method is used as an immunoreconstructive therapy, the decrease in immunologic competence which may be caused by the reduction in lymphocytes can be avoided and, therefore, the risk of the occurrence of an infectious disease can be decreased. | 2010-09-30 |
20100247580 | Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy - The present invention relates to gene expression profiles; methods for classifying patients; microarrays; and treatment of population of patients selected through use of methods and microarrays as described herein. | 2010-09-30 |
20100247581 | EDIBLE PRODUCT HAVING AN IMMUNOSTIMULATING EFFECT - There is provided an edible product having an immunostimulating effect, said product comprising immunostimulating polysaccharides obtainable from plants of the Asclepiadoideae subfamily. Also provided is a process for preparing such an edible product and a composition comprising from 0.0001 to 25% by weight of polysaccharides having an immunostimulating effect. | 2010-09-30 |
20100247582 | METHOD OF PREPARING FIBRE-CONTAINING PECTIN PRODUCT AND PECTIN PRODUCTS HEREOF - The present invention relates to a method for providing a fibre-containing pectin product from a plant material. The method comprises the steps of: (i) providing a plant material comprising pectin, where said pectin is having a degree of esterification of 55% or less, (ii) adding an acidic aqueous solution to the pectin containing plant material obtained in step (i) and providing a suspension of the plant material, where the suspended plant material provides an in situ system by swelling the plant material under conditions where the pectin is kept within the plant material, and (iii) obtaining the fibre-containing pectin product from the suspension provided in step (ii), wherein the plant material is substantially depleted from divalent cations. | 2010-09-30 |
20100247583 | NOVEL N-PHENYLACETAMIDE INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel N-phenylacetamide compounds of formula (I): | 2010-09-30 |
20100247584 | COMPOSITIONS USEFUL FOR TREATING GASTROESOPHAGEAL REFLUX DISEASE - The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount is from about one to about three daily doses of the compound and the dose is from about 0.2 mg to about 0.5 mg. | 2010-09-30 |
20100247585 | STABILIZED PHARMACEUTICAL PRODUCT - Use of an adsorbent and a sealed package (e.g. an overwrap) to protect a pharmaceutical product in a solid state in the presence of a reducing sugar. | 2010-09-30 |
20100247586 | Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties - A multi portion intra-oral dosage form has at least one pharmaceutically active agent or health promoting agent with at least one portion comprises a component for creating a noticeable organoleptic sensation. The sensory markers or signals are conceptual aids for a subject using the dosage form where the organoleptic sensation is such that it facilitates the subject to identify a portion and differentiate between different portions. Also contemplated are a dosage form, a method and a system for delivering active agents, such as nicotine and/or metabolites thereof, such as cotinine, nicotine N′-oxide, nomicotine, (S)-nicotine-N-β-glucuronide and mixtures, isomers, salts and complexes thereof as well as use and production of said dosage forms. | 2010-09-30 |
20100247587 | PIGMENTATION-REGULATING COMPOUNDS - The present invention relates to compounds of general formula (I): | 2010-09-30 |
20100247588 | Method For Preparing Finely Divided Emulsions - Finely divided emulsions, preferably for use in cosmetic preparations can be produced by first producing a microemulsion which contains at least 10-20% by weight of an alkyl(oligo)glycoside of general formula R | 2010-09-30 |
20100247589 | PEPTIDE COMPOSITIONS FOR ORAL CARE SYSTEMS - Oral care compositions, oral care systems, oral surface-binding peptides, and a method for applying particles to an oral surface are provided. The oral care system comprises at least one peptidic component comprising a first binding element having affinity for an oral surface and a second binding element having affinity for a ligand property of a particle. | 2010-09-30 |
20100247590 | Peptide-Based Systems For Delivery Of Cosmetic Agents - The present invention relates to compositions and systems comprising peptide-based reagents for delivery of cosmetic benefit agents to human hair, human skin, or human nail. | 2010-09-30 |
20100247591 | Skin Treatment Compositions Containing Copper-Pigment Complexes - A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the treatment of environmentally-induced premature skin aging, excessively oily skin, acne and acne-related skin disorders, acne-rosacea, and also stimulates the natural tanning response of skin to sunlight and other ultraviolet-containing radiation. | 2010-09-30 |
20100247592 | PROCESS FOR LIMITING THE GROWTH OF MICROORGANISMS - A process for limiting the growth of microorganisms comprises (a) providing an antimicrobial agent comprising fine-nanoscale gold on a support medium comprising nanoparticulate titania, the fine-nanoscale gold having been deposited on the support medium by physical vapor deposition; and (b) contacting at least one microorganism with the antimicrobial agent. | 2010-09-30 |
20100247593 | NOVEL COMPOUNDS AND PHARMACEUTICAL PREPARATIONS - Ectracts and pharmaceuticals form | 2010-09-30 |
20100247594 | DELIVERY OF DRY FORMULATIONS OF OCTREOTIDE - Methods and devices are described for delivering octreotide to a patient, comprising implanting a controlled release composition for delivering octreotide, wherein the composition does not require hydration prior to implantation, and wherein the composition optionally comprises a release agent. | 2010-09-30 |
20100247595 | POROUS STRUCTURES AND METHODS OF USE - The present invention provides porous structures that each comprise chitosan, alginate and divalent metal cations, wherein: (a) the chitosan is ionically linked to the alginate; and (b) the structure is porous and has a compressive yield strength of at least 0.35 MPa. The present invention also provides methods for making the porous structures, and methods for using the porous structures as substrates to grow living cells. | 2010-09-30 |
20100247596 | ELEMENT FOR IMPLANTATION WITH MEDICAL DEVICE - A therapeutic agent eluting element includes an elongate body member and one or more therapeutic agents elutable from the body member. The elongate body member is configured to be implanted subcutaneously along side of a therapy delivery element. The elongate body member may be formed from a polymeric material, and the agent eluting element may consist essentially of the body member and the one or more therapeutic agents. The therapeutic agent eluting element may be a part of a system or kit that includes a therapy delivery element and a tunneling tool, such as a dilator, sheath, catheter passer, or the like. | 2010-09-30 |
20100247597 | Biocompatible Polymers for Coating or Fabricating Implantable Medical Devices - The present disclosure generally relates to biocompatible polymers for coating or fabricating implantable medical devices and to implantable medical devices having the present biocompatible polymers. The disclosed biocompatible polymers exhibit superior biocompatibility and therefore minimize unwanted immune reaction from a patient into whom a medical device is implanted. | 2010-09-30 |
20100247598 | Thick foams for biomedical application and methods of making - A novel method of manufacturing thick foams, especially molded thick foams useful as tissue scaffolds and other medical devices. Also disclosed are novel thick foams made using the process of the present invention, wherein such thick foams may be used as medical devices or components of medical devices. | 2010-09-30 |
20100247599 | DRUG-RELEASING POLYELECTROLYTE COATING, METHOD FOR FORMING A DRUG-RELEASING POLYELECTROLYTE COATING, AND IMPLANTABLE DEVICE - A drug-releasing polyelectrolyte coating includes: (a) at least two oppositely charged polyelectrolyte layers; (b) at least one pharmaceutical active drug which is covalently coupled to polyelectrolytes of at least one of the polyelectrolyte layers; (c) wherein the drug exhibits a release rate from the polyelectrolyte coating of less than 50% in 3 days. | 2010-09-30 |
20100247600 | THERAPEUTIC DRUG ELUTING IMPLANT COVER AND METHOD OF MAKING THE SAME - A drug-eluting implant cover fabricated from a drug-eluting biocompatible matrix containing at least one elutable drug, a drug-eluting implant cover kit containing at least one drug-eluting implant cover, and a method of manufacturing the same. | 2010-09-30 |
20100247601 | REPAIR AND TREATMENT OF BONE DEFECT USING CELLS INDUCED BY AGENT PRODUCED BY CHONDROCYTES CAPABLE OF HYPERTROPHICATION AND SCAFFOLD - The present invention provides a method of inducing undifferentiated cells into induced osteoblasts. The method includes: A) a step of providing an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and B) a step of culturing the undifferentiated cells in an undifferentiated cell culture medium containing the induced osteoblast differentiation inducing agent and a medium component, to differentiate the undifferentiated cells into the induced osteoblasts. | 2010-09-30 |
20100247602 | METHOD OF REDUCING THE EFFECTS OF CYTOSTATIC DRUGS ON BONE MARROW DERIVED CELLS, AND METHODS OF SCREENING - A method of using an estrogen receptor agonist and antagonist to reduce a toxic effect of a cytostatic drug on bone marrow derived cells in a biological system. The methods comprise contacting the cells with a therapeutically effective amount of an estrogen receptor agonist or antagonist, and contacting the cells with a cytostatic agent, whereby the toxic effect of the cytostatic drug on bone marrow derived cells is reduced. Agonists disclosed include 17-beta-estradiol. Antagonists disclosed include antisense nucleic acids and selective estrogen receptor modulators (SERMs). Furthermore, uses and medicaments comprising estrogen receptor agonists and antagonists are provided, as are screening methods for identifying therapeutic candidates for reducing the effect of cytostatic agents, and methods of using estrogen receptor agonists for increasing the proliferation of CD117 | 2010-09-30 |
20100247603 | ARSENIC TRIOXIDE MEDICAL ELUTION SCAFFOLD - An arsenic trioxide medical elution scaffold and preparation method thereof, wherein the arsenic trioxide medical elution scaffold comprises scaffold, polymer coating covering the scaffold and arsenic trioxide loaded in the polymer coating which is in the form of single particle or particle conglomeration island. Animal experiments testify that the medical release of the arsenic trioxide medical elution scaffold is suitably uniform, and can be controlled to meet clinic requirement. | 2010-09-30 |
20100247604 | METHOD OF TREATMENT OF CONNECTIVE TISSUES AND ORGANS AND USES OF SAID TISSUES AND ORGANS - A method of treatment of connective tissue includes the steps of providing a biological tissue or organ, coating the tissue or organ with an enzymatic solution capable of phagocytizing at least partly fibroblasts, macrophages, mast cells and other cells responsible for immune and rejection reactions in homologous and heterologous transplantations. The biological tissue or organ, after the treatment with the enzymatic solution is irradiated with ionizing electromagnetic radiations in order to obtain an acellular tissue which maintains its own extracellular matrix unchanged. Preferably, such radiations are gamma radiations having a frequency between 10 | 2010-09-30 |
20100247605 | Three Dimensional Cell Protector/Pore Architecture Formation for Bone and Tissue Constructs - Living cellular material is encapsulated or placed in a protective material (cell protector) which is biocompatible, biodegradable and has a three-dimensional form. The three dimensional form is incorporated into a matrix that maybe implanted in vivo, ultimately degrade and thereby by replaced by living cell generated material. | 2010-09-30 |
20100247606 | INTRAOCULAR SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND METHODS FOR TREATING OCULAR CONDITIONS - Biocompatible, bioerodible sustained release implants and microspheres for intracameral or anterior vitreal placement include an anti-hypertensive agent and a biodegradable polymer effective to treat an ocular hypertensive condition (such as glaucoma) by relapsing therapeutic amount of the anti-hypertensive agent over a period of time between | 2010-09-30 |
20100247607 | IMPLANTABLE FORMULATIONS OF BISPHOSPHONIC ACIDS - The invention relates to devices, methods and formulation for subcutaneous administration of a bisphosphonate. In such a device, a drug core, comprising a bisphosphonate, is disposed in a tube. The devices may be administered to a patient in need of subcutaneously wherein the release of the bisphosphonate is desired to provide sustained release of a therapeutically effective dose of the bisphosphonate. | 2010-09-30 |
20100247608 | PHARMACEUTICAL COMPOSITIONS COMPRISING HGH FOR ORAL DELIVERY - The present invention relates to dosage forms of human growth hormone, the use of an absorption enhancer to allow absorption of human growth hormone into the systemic circulation in a biologically active form, in particular after oral administration, as well as the use of oral dosage forms comprising human growth hormone and an absorption enhancer for the treatment of human growth hormone deficiencies and disorders associated therewith. | 2010-09-30 |
20100247609 | PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading. | 2010-09-30 |
20100247610 | GASTRIC RETAINED GABAPENTIN DOSAGE FORM - A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form. | 2010-09-30 |
20100247611 | TITANIUM DIOXIDE NANOTUBES FOR PRODUCTION AND DELIVERY OF NITRIC OXIDE AND METHODS FOR PRODUCTION THEREOF - The present disclosure describes compositions operable for releasing nitric oxide under photochemical conditions. The compositions include a titanium dioxide nanomaterial and a nitric oxide-releasing compound deposited on the titanium dioxide nanomaterial that is operable to release nitric oxide under photochemical conditions. Titanium dioxide nanomaterials include, for example, titanium dioxide nanotubes. To facilitate the photochemical release of nitric oxide, some embodiments of the compositions further include a semiconductor that is deposited on the titanium dioxide nanotubes. Both the semiconductor and the nitric oxide-releasing compound may be deposited on the interior surface, exterior surface, or both of the titanium dioxide nanotubes. A polymer may wrap the titanium dioxide nanotubes to protect the nitric oxide-releasing compounds from moisture. Also disclosed herein are methods for producing such compositions and medical devices obtained therefrom. | 2010-09-30 |
20100247612 | EXTRUDABLE AND EXTRUDED COMPOSITIONS FOR DELIVERY OF BIOACTIVE AGENTS, METHOD OF MAKING SAME AND METHOD OF USING SAME - A nonaqueous, extrudable composition includes at least one thermoplastic polymer in an amount of more than 20 wt % of the whole composition and tobacco. An extruded bioactive product in the form of a sheet can be made by extruding or hot melt shaping a nonaqueous composition comprising at least one thermoplastic polymer and a bioactive agent, the sheet being soluble in a user's mouth and resulting in sustained release of bioactive to the user. The sheet can be in a form that may be placed in contact with the mucosa of the user, and have an average dissolution time of 5 to 50 minutes for delivering the bioactive to the user. | 2010-09-30 |
20100247613 | Dressing Modified to Receive Medicine - A laminated dressing defining an area adapted to receive and hold medicine. In one embodiment of the invention, the dressing comprises a contact layer and a backing layer, both fabricated from absorbent materials. The contact layer has an inboard surface and an opposing outboard surface defined. The outboard surface of the contact layer is adapted to be applied to a patient's skin surrounding a wound. The contact layer further defines a die-cut through-opening substantially in the center of the contact layer. Adhering to the inboard surface of the contact layer is the backing layer, which likewise has an inboard surface and an opposing outboard surface defined. Medicine is received in the area defined by the through-opening in the contact layer and the inboard surface of the backing layer. A polymer film covers the outboard surface of the backing layer to prevent the escape of medicine from the dressing through the backing layer. A removable release film covers the adhesive-covered outboard surface of the contact layer, the reception area and the medicine until the dressing is ready to be used. | 2010-09-30 |
20100247614 | HEMOSTATIC WOUND DRESSING - Hemostatic wound dressings that include cationic polymers and related hydrogels, methods for making and using the wound dressings. | 2010-09-30 |
20100247615 | Superabsorbent Materials Comprising Peroxide - This invention pertains to a polymeric composition and an antimicrobial composition, each comprising a superabsorbent polymer (SAP), such as used in diapers and sanitary napkins, and peroxide. The superabsorbent material can be made by the process of treating a preformed SAP, such as a crosslinked polyacrylate salt, with a treatment solution comprising hydrogen peroxide dissolved in water, followed by drying. The resulting superabsorbent material has strong antimicrobial activity. Optionally, the treatment solution may also contain a metal salt, including those of zinc, zirconium, and magnesium. | 2010-09-30 |
20100247616 | PATCH AND PATCH PREPARATION - The present invention provides a patch and a patch preparation having an adhesive layer with a sufficient thickness, as well as appropriate skin adhesiveness and flexibility, which resist falling off from the skin even when a load is applied to the side opposite to the surface of the patch or patch preparation to be adhered to the skin, i.e., an exposed surface of a support of the patch or patch preparation, and show low irritation to the skin; an adhesive layer, which is obtained by crosslinking a liquid rubber having a crosslinkable functional group in a molecule in the presence of a crosslinking agent having a functional group number of 3 or below and a catalyst, on at least one surface of a support; and a patch preparation having an adhesive layer containing a pharmaceutical agent. | 2010-09-30 |
20100247617 | Transdermal Administration Of (2S)-(4E)-N-Methyl-5-(3-(5-Isopropoxypyridin)yl)-4-Penten-2-Amine - The present invention generally relates to the transdermal administration of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or pharmaceutically acceptable salts thereof. The transdermal administration can be effected using transdermal drug delivery devices, semi-solid dosage forms, or iontophoresis. The drug delivery devices and/or semi-solid dosage forms can provide instantaneous release, sustained release, or combinations thereof, and can include permeation enhancers and other components to assist in drug transport across the dermis, especially the epidermis. The compositions can be used to treat and/or prevent any indication which the active ingredients are capable of treating and preventing, but deliver (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or pharmaceutically acceptable salts thereof, in an efficacious manner. Disorders that can be treated and/or prevented include central nervous system disorders, addictions, pain, and inflammation. | 2010-09-30 |
20100247618 | Novel synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV - The present invention relates to peptides, referred to as CBD-1, CBD-2, CBM-1/TH-1, CBM-1/TH-2, CBM-2/TH-1, CBM-2/TH-2 and C-20 peptides, which are antigenic and elicit protective immune response against HIV infection. Compositions, pharmaceutical compositions and vaccines comprising these antigenic peptides are also encompassed by the present invention, as well as neutralizing antibodies which inhibit infection of primary CD4+ T lymphocytes by various HIV isolates. Methods for diagnosis of HIV are also disclosed. | 2010-09-30 |
20100247619 | Nanostructured Lipid Carriers Containing Riluzole And Phamaceutical Formulations Containing Said Particles - This invention relates to nanoparticles consisting of riluzole trapped in lipids, and their use to prepare medicinal products for the treatment of Amyotrophic Lateral Sclerosis and Multiple Sclerosis. | 2010-09-30 |
20100247620 | Methods for co-encapsulation of combination drugs and co-encapsulated combination drug product - This invention is for an improved process to co-encapsulate hydrophobic drugs and hydrophilic drugs in phospholipid liposomes. Non-toxic supercritical or near-critical fluids with/without polar cosolvents are utilized to solubilize phospholipid materials and hydrophobic drugs, and form uniform liposomes to encapsulate hydrophobic drugs and hydrophilic drugs. | 2010-09-30 |
20100247621 | CODON MODIFIED IMMUNOGENIC COMPOSITIONS AND METHODS OF USE - The present invention features immunogenic compositions comprising codon modified genes that encode viral proteins and/or glycoproteins or fragments. The immunogenic compositions of the invention are useful in various methods of treatment, such as preventing or treating viral infection. Also provided in the present invention are kits and instructions for use. | 2010-09-30 |
20100247622 | TREATMENT REGIME FOR PROLIFERATIVE DISORDERS - Provided herein are methods for treating or ameliorating a proliferative disorder in a subject. The method contains the steps of administering to the subject one dose of an immunosuppressive agent followed by administering to the subject one to five doses of a reovirus. The immunosuppressive agent is administered to the subject at least about 72 hours prior to administration of the reovirus. Also provided herein are methods for treating or ameliorating a proliferative disorder in a subject including the steps of administering to the subject an oncolytic virus and a B-cell modulating agent. Also provided are kits and pharmaceutical compositions containing an oncolytic virus and at least one B-cell modulating agent. | 2010-09-30 |
20100247623 | Cancer Stem Cell Vaccine - The invention provides a method of making a vaccine for treating or preventing cancer in a patient or individual which comprises preparing the vaccine from cancer stem cells, from fractions, extracts, shed material or purified antigens derived from these cells, or from DNA or RNA coding for cancer stem cell associated antigens. In one embodiment of this invention, cancer stem cells are separated from unrelated cancer cell populations and then expended and cultured under conditions in which the cancer stem cells shed or release tumor antigens, and using the shed material or cancer stem cell antigens isolated from it as the vaccine. The invention further provides a vaccine and methods of treatment using the vaccine for any cancer is disclosed. Also disclosed are specific applications of this method to prepare such vaccines from antigens released or shed by cancer stem cells, and a particular application to make a shed, cancer stem cell, vaccine for breast cancer. | 2010-09-30 |
20100247624 | VACCINE COMPOSITIONS AND METHODS CONTAINING AN IMMUNOGEN DERIVED FROM EQUINE ARTERITIS VIRUS - The present invention relates to vaccine compositions comprising a nucleic acid encoded by an equine arterivirus virus (EAV) open reading frame (ORF) 2 nucleic acid, and a nucleic vector comprising said EAV ORF 2. The invention further relates to the methods and kits encompassing the use of EAV ORF 2 containing vaccine compositions and nucleic acid vectors for the prevention and/or treatment of EAV infections. | 2010-09-30 |
20100247625 | Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof. | 2010-09-30 |
20100247626 | PEGYLATED COMPOUNDS FOR AGE-RELATED MACULAR DEGENERATION - A special photosensitizer formulation and Photodynamic Therapy method for treating choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) is provided. CNV is a major cause for vision loss in elderly patients. A special drug delivery formulation is used to encapsulate the hydrophobic photosensitizer, preferably a pegylated liposome. This improves the solubility and therapeutic index of the photosensitizers. In one preferred embodiment, a pegylated photoactive agent remains confined in the intravascular compartment of neovasculature for a longer duration. Thus efficient elimination of neovascular proliferation and minimal damage to extravascular tissue and normal vessels is ensured. In this method, a hydrophobic photosensitizer, that is able to photochemically destroy neovessels, is injected into the patient. CNV irradiation with a non-thermal laser follows after a predefined time interval. The excited photosensitizer photocoagulates newly formed blood vessels thereby improving the vision and preventing further loss of vision. | 2010-09-30 |
20100247627 | FOXN1 AND PIGMENTATION - The present invention provides methods and compositions for modulating skin pigmentation. | 2010-09-30 |
20100247628 | Skin Treatment Compositions Containing Copper-Pigment Complexes - This invention discloses compositions and method for treating various types of skin disorders, based on topical cutaneous delivery of copper chemically bound with botanical pigments. Sodium-copper-chlorophyllin is used as an example, showing benefits in the treatment of rosacea, acne, oily skin, enlarged pores, and in relieving skin inflammation. Benefits are also disclosed in treatment of environmentally caused premature skin aging, via reductions in fine facial lines and wrinkles, increased tensile strength of the skin, and increased protection against sunlight via increased production of melanin. Therapeutic outcomes are improved when the copper-pigment complex is enclosed within submicron liposomes. | 2010-09-30 |
20100247629 | Method for drug loading in liposomes - A liposome composition having a protonatable therapeutic agent entrapped in the form of a salt with a glucuronate anion is disclosed. Methods for preparing the composition using an ammonium ion transmembrane gradient having glucuronate as the counterion are also disclosed. In one embodiment where the protonatable agent is doxorubicin, the method of the invention has comparable loading efficiency, faster release rate, without compromising the therapeutic efficacy compared to loading with an ammonium ion gradient having sulfate as the counterion. | 2010-09-30 |
20100247630 | Skin Treatment Compositions Containing Copper-Pigment Complexes - A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the treatment of environmentally-induce premature skin aging, excessively oily skin, acne and acne-related skin disorders, acne-rosacea, and also stimulates the natural tanning response of skin to sunlight and other ultraviolet-containing radiation. | 2010-09-30 |
20100247631 | PREPARATIONS FOR THE EXTERNAL APPLICATION OF ANTISEPTIC AGENTS AND/OR AGENTS PROMOTING THE HEALING OF WOUNDS - The present invention relates to liposomal pharmaceutical preparations which include active agents such as antiseptic agents, wound-healing agents, or combinations thereof, useful in the treatment of external wounds. The active agents are encapsulated in liposomes, and the liposomes are incorporated in pharmaceutical preparations such as liquids, ointments, gels, lotions, or creams capable of delivering the active agents to external wound sites. The invention further relates to methods of preparation of the liposomes and the pharmaceutical preparations, and to methods of treatment of external wounds and ophthalmic infections. | 2010-09-30 |
20100247632 | STABILIZED SOLUBILITY-ENHANCED FORMULATIONS FOR ORAL DELIVERY - Methods and compositions are described whereby poorly water-soluble beneficial agents such as vitamins and co-factors are formulated into self-emulsifying formulas (SEF) and optionally sorbing the SEF into pores of porous solid particulates, or preparing supersaturated solutions (SSS) and sorbing the SSS into pores of porous solid particulates. These formulations are useful as dosage forms with oral availability. | 2010-09-30 |
20100247633 | Polypeptide Films and Methods - Disclosed herein are polypeptide multilayer films comprising a hybrid polypeptide comprising a first polypeptide segment and a second segment, the two segments being covalently joined by one or more non-peptidic linkages. The first segment comprises a polypeptide having a magnitude of net charge per residue of greater than or equal to 0.4, and a length of greater than or equal to about 12 amino acid residues. The second segment comprises a polypeptide or another polyelectrolyte. | 2010-09-30 |
20100247634 | Compositions and Methods for Inhibiting Gastric Acid Secretion - The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor and one or more small carboxylic acid molecules as parietal cell activators in the gastric lumen. Unexpectedly, the compositions of the present invention are capable of enhancing the anti-acid activity of PPI in the stomach. The present invention further relates to a method of using such compositions to reduce gastric acid secretion in a mammal. | 2010-09-30 |
20100247635 | PHARMACEUTICALLY ACCEPTABLE SOLUBILIZING COMPOSITION AND PHARMACEUTICAL DOSAGE FORM CONTAINING SAME - A pharmaceutically acceptable solubilizing composition comprising (i) at least one tocopheryl compound having a polyalkylene glycol moiety and (ii) at least one alkylene glycol fatty acid monoester or mixture of alkylene glycol fatty acid mono- and diester is disclosed. The solubilizing composition is useful in the manufacture of a pharmaceutical dosage form which comprises a melt-processed mixture of at least one active ingredient, at least one pharmaceutically acceptable polymer. The active ingredient(s) may be inhibitors of HIV protease. The solubilizing composition enhances the bioavailability of the active ingredient after oral intake. | 2010-09-30 |
20100247636 | Nanoparticulate and controlled release compositions comprising nilvadipine - The present invention provides a composition comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, useful in the treatment and prevention of hypertension or related cardiovascular disorders. In one embodiment, the composition comprises nanoparticulate particles comprising nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers nilvadipine, or a salt, derivative, prodrug, or polymorph thereof, in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of hypertension or related cardiovascular disorders. | 2010-09-30 |
20100247637 | COMPOSITIONS AND PHARMACEUTICAL FORMS FOR THE ORAL ADMINISTRATION OF THYROID HORMONES ABLE TO COMBAT THE ACTION OF SEQUESTRANTS IN THE GASTROINTESTINAL TRACT - The invention concerns the use of a substance chosen among animal or vegetable gelatine, peptones, dextrins, native or modified cyclodextrins, starch, and starch hydrolysates in the preparation of pharmaceutical forms for the oral administration of thyroid hormones to combat the action of sequestrant agents present in the gastrointestinal tract, and related pharmaceutical forms. | 2010-09-30 |
20100247638 | ORGANOLEPTICALLY IMPROVED DIETARY FIBER COMPOSITION AND A PROCESS THEREOF (TEESTAR) - The present invention is in relation to an organoleptically improved dietary fiber composition from | 2010-09-30 |
20100247639 | COATED PHARMACEUTICAL OR NUTRACEUTICAL PREPARATION WITH ENHANCED ACTIVE SUBSTANCE RELEASE IN THE COLON - The present invention relates to a pharmaceutical or nutraceutical preparation comprising a) a core containing a pharmaceutically or nutraceutically active substance; and b) an inner controlling layer surrounding the core comprising i) one or a mixture of a plurality of (meth)acrylate copolymers bearing a cationic group or a group that can be converted to a cationic group; and ii) one or a mixture of a plurality of polymers or copolymers bearing an anionic group or group that can be converted to an anionic group; and c) an outer controlling layer comprising one or a mixture of a plurality of polymers or copolymers bearing an anionic group or group that can be converted to an anionic group and to tablets or capsules comprising same. | 2010-09-30 |
20100247640 | Solid Oral Dosage Form Containing An Enhancer - The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form. | 2010-09-30 |
20100247641 | MECHANICAL PROTECTIVE LAYER FOR SOLID DOSAGE FORMS - The present invention relates to a mechanical protective layer for pellets comprising at least two plasticizer agents, to a method for preparing the same and to a solid dosage form comprising the same. | 2010-09-30 |
20100247642 | STABLE PHARMACEUTICAL FORMULATION FOR A DPP-IV INHIBITOR - A dosage form is provided for an anti-diabetic DPP-IV inhibitor of formula (I) as its tartarate salt, wherein the purity of the active pharmaceutical ingredient is maintained over a prolonged storage period under conditions similar to those likely encountered in home storage of the medication by a diabetic patient. A formulation free of calcium salts such as calcium phosphate, but including microcrystalline cellulose, copovidone, crospovidone, colloidal silicon dioxide, and magnesium stearate, when compacted into a tablet with the active pharmaceutical ingredient, was shown to be stable for at least six months at 40° C. and 75% relative humidity. Methods for preparation of the dosage form are also provided. | 2010-09-30 |
20100247643 | Oral formulations - A solid pharmaceutical composition containing AP23573 suitable for oral administration is disclosed. | 2010-09-30 |
20100247644 | ADHESIVE COMPOSITIONS FOR THE TREATMENT OF XEROSTOMIA - Compositions for the treatment of xerostomia, and methods of making and using thereof are disclosed herein. The compositions are typically in the form of a film or tablet, such as a double layer sticker tablet. The compositions adhere to a buccal surface or mucosal surface in the oral cavity for at least 15 minutes, preferably for at least 30 minutes. The compositions themselves are able to increase the levels of saliva in the mouth without the need for active agents, such sialogogic agents. The compositions optionally contain a non-lipid lubricant, a flavoring agent, and/or a buffering agent. The composition is generally effective at treating or ameliorating the effects of xerostomia for a time period ranging from at least 30 minutes up to eight hours following administration to the buccal or oral mucosa. | 2010-09-30 |
20100247645 | PHARMACEUTICAL COMBINATION OF ALISKIREN AND VALSARTAN - The present invention relates to a pharmaceutical oral fixed dose combination comprising
| 2010-09-30 |
20100247646 | EXTENDED RELEASE TABLETS OF NISOLDIPINE - The present invention relates to extended release tablets comprising a core which comprises of nisoldipine, a rate-controlling hydrophilic polymer and optionally, an enteric agent. Such tablets may also be coated with a release rate-controlling coating comprising of a hydrophobic polymer or enteric agent or combinations thereof, in particular ethylcellulose, and Eudragits. | 2010-09-30 |
20100247647 | SUSTAINED RELEASE TABLETS WITH HYDROMORPHONE - The invention relates to a tablet having a tablet core comprising a plurality of active ingredient-containing pellets and one or more pharmaceutically tolerated excipients and at least one coating applied to the tablet core, the active ingredient-containing pellets containing hydromorphone or a salt or a solvate thereof as active ingredient and having the following structure:
| 2010-09-30 |
20100247648 | ANTIMICROBIAL COMPOUNDS - The invention relates to compositions comprising a compound based on the general formula (I) | 2010-09-30 |